Is there any generic drug of Elacetrant on the market and analysis of the market prospects of generic drugs

Elacetrant (Elacestrant) is not currently available in mainland China, so domestic patients are temporarily unable to purchase the drug. The original drug has not yet been approved in the Chinese market, and there are no legal domestic sales channels for generic drugs. This also means that if patients need to use the drug, they must go through formal overseas channels and receive treatment under the guidance of professional doctors.

In foreign markets, the European version of the original drug, ilastrast, is more expensive, about more than 30,000 yuan per box, and the cost is a heavy burden for most patients. In contrast, the price of generic drugs produced in Laos is more affordable, about more than 2,000 yuan per box, and the drug ingredients are basically the same as the original drugs, providing overseas patients with a relatively economical choice.

As the efficacy of elastran in ERpositive, HER2negative, ESR1 mutated advanced or metastatic breast cancer is recognized, its market demand is gradually increasing. In the future, as patents expire and domestic drug approval policies are gradually improved, it is expected that generic drugs may be launched in the country, thereby providing patients with more economical and accessible medication options.

At present, patients cannot obtain elastran through formal channels in China, and the use of the drug must follow the guidance of a doctor and be combined with existing treatment plans. After generic drugs are launched in the future, appropriate drugs should be selected based on drug ingredients, quality and economic conditions, while efficacy and safety should be closely monitored to achieve the best therapeutic effect.

Reference materials:https://www.drugs.com/